[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100392359":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":27,"responsibleParty":63,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":10,"maxAge":74,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Shaare Zedek Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Gaucher disease patients",null,"Patients with type 1,2,3 Gaucher disease.",{"label":13,"type":10,"description":14,"interventionNames":10},"GBA carriers with Parkinson disease","Patients with Parkinson disease GBA related (carriers)",[16],{"name":17,"affiliation":5,"role":18},"Ari Zimran, MD","PRINCIPAL_INVESTIGATOR",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Majdolen Istaiti, BS.C","CONTACT","+972-2-5645681","joleenist@szmc.org.il",{"name":17,"role":22,"phone":23,"phoneExt":10,"email":26},"azimran@gmail.com",[28,49,55],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"RECRUITING","Jerusalem","Please Select...","9103102","Israel","IL",{"type":36,"coordinates":37},"Point",[38,39],35.21633,31.76904,{"lat":39,"lon":38},[42,45,47],{"name":43,"role":22,"phone":44,"phoneExt":10,"email":26},"Ari Zimran, M.D.","+97226555143",{"name":46,"role":22,"phone":44,"phoneExt":10,"email":24},"Joleen Istaiti, MBA",{"name":48,"role":18,"phone":10,"phoneExt":10,"email":10},"Ari Zimran, Prof.",{"facility":5,"status":29,"city":30,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},{"type":36,"coordinates":51},[38,39],{"lat":39,"lon":38},[54],{"name":48,"role":18,"phone":10,"phoneExt":10,"email":10},{"facility":5,"status":29,"city":30,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},{"type":36,"coordinates":57},[38,39],{"lat":39,"lon":38},[60,62],{"name":61,"role":22,"phone":44,"phoneExt":10,"email":24},"Joleen Istaiti, BS.c",{"name":17,"role":22,"phone":44,"phoneExt":10,"email":26},{"type":18,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ari Zimran","Principal Investigator","100392359","world-data-on-ambroxol-for-patients-with-gd-and-gba-related-pd-100392359",false,"NCT04388969","World Data on Ambroxol for Patients With GD and GBA Related PD","IIR REGISTRY for the Collection of Real World Data on the Safety and Efficacy of Ambroxol for Patients With Gaucher Disease or GBA Carriers With Parkinson Disease","Inclusion Criteria:\n\n* patients with Gaucher disease type 1,2 or 3(a,b,c).\n* patients with GBA-related Parkinson disease.\n\nExclusion Criteria:\n\n* None.","ALL","100 Years",{"count":76,"type":77},300,"ESTIMATED","OBSERVATIONAL","Ambroxol hydrochloride is an oral mucolytic drug available over-the-counter for many years as cough medicine. In 2009 it was found to also act as a pharmacological chaperone (PC) for mutant glucocerebrosidase, albeit in a several-fold higher dose. Unfortunately, due to its low cost, there have been no pharma-driven clinical trials to establish the use of ambroxol. Thus, data are needed on the safety and efficacy of ambroxol for patients with Gaucher disease (GD).",[81,82,83],"Gaucher Disease","Parkinson Disease","GBA Gene Mutation",[85,81,13],"Ambroxol","2026-04-23",{"date":88,"type":89},"2026-04-29","ACTUAL",{"date":91,"type":89},"2020-05-06",{"date":93,"type":77},"2030-11-30",{"name":5,"class":6},3]